Lag-3, Tim-3, and TIGIT co-inhibitory receptors with specialized functions in immune regulation

By A. Anderson, N. Joller, V. Kuchroo. Immunity, 2016

1,913 citations recorded by the source corpus.

Summary Co-inhibitory receptors, such as CTLA-4 and PD-1, have an important role in regulating T cell responses and have proven to be effective targets in the setting of chronic diseases where constitutive co-inhibitory receptor expression on T cells dampens effector T cell responses. Unfortunately, many patients still fail to respond to therapies that target CTLA-4 and PD-1. The next wave of co-inhibitory receptor targets that are being explored in clinical trials include Lag-3, Tim-3, and TIGIT. These receptors while belonging to the same class of receptors as PD-1 and CTLA-4 exhibit unique functions especially at tissue sites where they regulate distinct aspects of immunity. Increased understanding of the specialized functions of these receptors will inform the rational application of therapies that target these receptors to the clinic.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/21d365009f18318607c8bfb2a059805b6f695a2f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Charles G. Drake
2. J. Bluestone

Citations in the corpus

• CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment (2019, background): “(CD112), PVRL3 (113) activation), undergo remodeling during glycolysis, lose function and release detrimentally high levels of ROS.”
• LAG3 (CD223) as a Cancer Immunotherapy Target (2017, background): “Residues: Red = EP residues within the EP motif region; Blue = conserved residues (100%); Purple = semi-conserved residues (>85% - 25/29[4]); Green = dominant residues (>60% - 18/29[11]).”
• Next generation of immune checkpoint therapy in cancer: new developments and challenges (2018, background): “Presence of TIM-3+ T cells correlates with severity and poor prognosis in non-small cell lung carcinoma (NSCLC) and follicular lymphoma [11].”
• Defining T cell states associated with response to checkpoint immunotherapy in melanoma (2018, neutral): “We found that while CD8CD39 and CD8CD39 T cells had equal expression of PD-1, CD39 turned out to be a key marker that separates all TIM3 from TIM3 cells (Figure S4C), the latter being reported as a marker of T cell dysfunction in cancer and chronic infections (Anderson et al., 2016).”
• Single-cell RNA-seq and computational analysis using temporal mixture modelling resolves Th1/Tfh fate bifurcation in malaria (2017, background): “These findings may also apply to other IRs (4, 14), whose intrinsic effect on Tregs might have been previously overlooked.”
• Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 (2019, background): “Subsequently, it was described by other groups with each group giving a different name including WUCAM [96], Vstm3 [97], and Vsig9 [98].”
• CD28 costimulation: from mechanism to therapy (2016, background): “Other members of the subfamily include Immunity 44, May 17, 2016 ª 2016 Elsevier Inc. 973 ICOS, CTLA4, PD1, PD1H, TIGIT, and BTLA (Chen and Flies, 2013; Anderson et al., 2016 in this issue).”